GSTM1 and myocardial infarction: Three large RCTs in patients with CKD not yet on dialysis have been completed [6–8] and found no evidence of benefits of a higher (compared with lower) Hb target on cardiovascular events or a composite outcome of death, myocardial infarction, hospitalization for congestive heart failure and stroke, or they found increased risk of adverse events.